Literature DB >> 16898071

Penetration of ASM 981 in canine skin: a comparative study.

Meret E Ricklin Gutzwiller1, Martin Reist, Elke Persohn, John E Peel, Petra J Roosje.   

Abstract

ASM 981 has been developed for topical treatment of inflammatory skin diseases. It specifically inhibits the production and release of pro-inflammatory cytokines. We measured the skin penetration of ASM 981 in canine skin and compared penetration in living and frozen skin. To make penetration of ASM 981 visible in dog skin, tritium labelled ASM 981 was applied to a living dog and to defrosted skin of the same dog. Using qualitative autoradiography the radioactive molecules were detected in the lumen of the hair follicles until the infundibulum, around the superficial parts of the hair follicles and into a depth of the dermis of 200 to 500 microm. Activity could not be found in deeper parts of the hair follicles, the dermis or in the sebaceous glands. Penetration of ASM 981 is low in canine skin and is only equally spread in the upper third of the dermis 24 hours after application. Penetration in frozen skin takes even longer than in living canine skin but shows the same distribution.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16898071     DOI: 10.1007/BF03191119

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  16 in total

Review 1.  The ACVD task force on canine atopic dermatitis (XIX): general principles of therapy.

Authors:  T Olivry; C A Sousa
Journal:  Vet Immunol Immunopathol       Date:  2001-09-20       Impact factor: 2.046

Review 2.  Animal models of atopic dermatitis.

Authors:  Rosanna Marsella; Thierry Olivry
Journal:  Clin Dermatol       Date:  2003 Mar-Apr       Impact factor: 3.541

3.  Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus.

Authors:  Andreas Billich; Heinrich Aschauer; András Aszódi; Anton Stuetz
Journal:  Int J Pharm       Date:  2004-01-09       Impact factor: 5.875

4.  Effects of freezing on human skin permeability.

Authors:  S M Harrison; B W Barry; P H Dugard
Journal:  J Pharm Pharmacol       Date:  1984-04       Impact factor: 3.765

5.  First experience of topical SDZ ASM 981 in children with atopic dermatitis.

Authors:  J Harper; A Green; G Scott; E Gruendl; B Dorobek; M Cardno; P Burtin
Journal:  Br J Dermatol       Date:  2001-04       Impact factor: 9.302

6.  The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils.

Authors:  T Zuberbier; S U Chong; K Grunow; S Guhl; P Welker; M Grassberger; B M Henz
Journal:  J Allergy Clin Immunol       Date:  2001-08       Impact factor: 10.793

Review 7.  Ascomycins: promising agents for the treatment of inflammatory skin diseases.

Authors:  C Paul; M Graeber; A Stuetz
Journal:  Expert Opin Investig Drugs       Date:  2000-01       Impact factor: 6.206

8.  A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology.

Authors:  M Grassberger; T Baumruker; A Enz; P Hiestand; T Hultsch; F Kalthoff; W Schuler; M Schulz; F J Werner; A Winiski; B Wolff; G Zenke
Journal:  Br J Dermatol       Date:  1999-08       Impact factor: 9.302

Review 9.  Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity.

Authors:  A Stuetz; M Grassberger; J G Meingassner
Journal:  Semin Cutan Med Surg       Date:  2001-12

Review 10.  Pimecrolimus: a review.

Authors:  A K Gupta; M Chow
Journal:  J Eur Acad Dermatol Venereol       Date:  2003-09       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.